Successful Clinical Inspection Reinforces PRU’s Commitment to GCP Standards
The Pharmaceutical Research Unit (PRU) is pleased to announce the successful completion of a clinical inspection conducted by the Kazakhstani National Centre for Expert Examination of Medicines and Medical Devices (NDDA). This study-based inspection reaffirms PRU’s alignment with international Good Clinical Practice (GCP) standards.
This achievement highlights our continuous dedication to maintaining the integrity, transparency, and quality of our clinical operations. By meeting the rigorous expectations of global regulatory bodies, PRU continues to demonstrate its readiness to support multinational pharmaceutical development and regulatory submissions.
At the core of our mission is an unwavering commitment to patient safety, regulatory compliance, and operational excellence. The positive outcome of this inspection is a reflection of the strong systems, capable teams, and quality culture that define PRU.
As we expand our global footprint, we remain driven by one goal: delivering reliable, high-standard bioequivalence studies that meet the needs of regulators and partners worldwide.
